Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Injectable MPL allergy vaccine - Allergy Therapeutics

Drug Profile

Injectable MPL allergy vaccine - Allergy Therapeutics

Alternative Names: Birch pollen allergen extract; Birch pollen modified allergen tyrosine-absorbed; Grass MATA MPL; Grass pollen modified allergen tyrosine-adsorbed; Pollinex Quattro; Pollinex Quattro Grass; Pollinex Quattro Tree; Pollinex Quattro® Birch; PQ Birch; PQ Grass; Tree MATA MPL

Latest Information Update: 06 Feb 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Allergy Therapeutics
  • Class Allergens; Antiallergics; Plant allergy immunotherapies
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Marketed Grass pollen hypersensitivity; Tree pollen hypersensitivity
  • Phase III Allergic rhinoconjunctivitis
  • Phase II/III Seasonal allergic rhinitis

Most Recent Events

  • 01 Nov 2023 Allergy Therapeutics completes a phase-III clinical trials in Allergic rhinoconjunctivitis (Prevention) in the USA, Austria, Czechia, Germany, Hungary and Poland (SC) (EudraCT2019-001517-16) (NCT05540717)
  • 11 Jun 2023 Efficacy data from a phase II/III trial in Grass pollen hypersensitivity released by Allergy Therapeutics
  • 21 Jul 2022 Phase-III clinical trials in Allergic rhinoconjunctivitis (Prevention) in Hungary (SC) (EudraCT2019-001517-16) (NCT05540717)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top